Holen Sie sich die Stockscreener-App
63.78
2.84%
1.76
Vorhandelsmarkt:
63.60
-0.18
-0.28%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$62.02
Offen:
$62.54
24-Stunden-Volumen:
2.84M
Relative Volume:
1.56
Marktkapitalisierung:
$31.11B
Einnahmen:
$10.63B
Nettoeinkommen (Verlust:
$819.00M
KGV:
38.47
EPS:
1.6577
Netto-Cashflow:
$1.59B
1W Leistung:
-14.33%
1M Leistung:
-18.24%
6M Leistung:
-19.71%
1J Leistung:
-32.71%
1-Tages-Spanne:
$62.49
$64.41
1-Wochen-Bereich:
$61.84
$67.66
52-Wochen-Spanne:
$61.84
$95.06
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
63.78 | 30.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
ISRG
Intuitive Surgical Inc
|
431.87 | 148.77B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.51 | 39.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
38.55 | 33.19B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
203.79 | 28.83B | 5.54B | 1.52B | 1.74B | 10.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Earnings call transcript: Alcon Q1 2026 sees EPS beat but stock dips - Investing.com Canada
Alcon Inc stock (CH0432492467): Eye health leader navigates surgical and vision care markets - AD HOC NEWS
Alcon Inc. stock (CH0432492467): Eye care leader reports Q1 2026 momentum - AD HOC NEWS
Alcon declines 10% after Q1 revenue misses consensus - MSN
Alcon Inc stock (CH0432492467): Eye health leader navigates market challenges - AD HOC NEWS
Alcon Inc. stock (CH0432492467): Eye health leader navigates market dynamics - AD HOC NEWS
Alcon Inc. (ALC) Stock Analysis: Eyeing a 41% Upside Potential Amid Robust Healthcare Growth - DirectorsTalk Interviews
Free float of ALCON N 2.LINIE – SIX:ALCE - TradingView
Return on assets % of ALCON N 2.LINIE – SIX:ALCE - TradingView
Alcon Inc. stock (CH0432492467): Eye care giant eyes growth in contact lenses and surgery devices - AD HOC NEWS
Enterprise value of Alcon AG TEMP – SIX:ALCE - TradingView
ALCON N 2.LINIE Cash Flow – SIX:ALCE - TradingView
Alcon Inc stock (CH0432492467): Eye care specialist reports mixed Q1 results and updates outlook - AD HOC NEWS
ALCON N 2.LINIE Statistics – SIX:ALCE - TradingView
ALCON N 2.LINIE Balance Sheet – SIX:ALCE - TradingView
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX) - The Globe and Mail
Number of shareholders of Alcon AG – MIL:1ALC - TradingView
Alcon Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:ALC) 2026-05-08 - Seeking Alpha
Mizuho Securities Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $85 - Moomoo
Alcon Inc. stock (CH0432492467): 10% sales growth and $1.5B buyback lift shares - AD HOC NEWS
LENSAR signals 2027 as really, really good year as it rebuilds distributor orders after Alcon deal termination - MSN
Tranche Update on Alcon Inc.'s Equity Buyback Plan announced on February 25, 2025. - marketscreener.com
Needham tracks April prescription trends for Alcon and Bausch + Lomb eye drugs - Investing.com Canada
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $110.2 - Moomoo
Bernstein Keeps Alcon at Outperform After Q1 Results; Estimates, Price Target Revised - Moomoo
Alcon Inc stock (CH0432492467): Eye care specialist eyes growth in contact lenses and surgery device - AD HOC NEWS
Alcon (ALC) Gets a Buy from RBC Capital - The Globe and Mail
ALC Maintains Overweight Rating -- Price Target Lowered to $86.0 - GuruFocus
ALC Maintains Rating by Baird -- Price Target Lowered to $90 - GuruFocus
ALC Maintains by Mizuho -- Price Target Lowered to $85.00 - GuruFocus
RBC Capital Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $102.37 - Moomoo
Here's why Alcon (ALC) is a strong value stock - MSN
Fewer cataract surgeries slow Alcon - WFMZ.com
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $70.65 to $102.76 - Moomoo
Here's Why Alcon (ALC) is a Strong Value Stock - Yahoo Finance
Alcon forecasts 5%-7% sales growth and announces $1.5B share repurchase program amid reduced tariff assumption - MSN
Alcon Reports First Quarter Growth Boosted by New Product Launches - VisionMonday.com
Needham Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $95 - Moomoo
Alcon Q1 2026 Sales Rise 10% as New Eye-Care Products Power Growth and $1.5 Billion Buyback - The Globe and Mail
Alcon: Results weren't bad; today's correction is a buying opportunity - marketscreener.com
Alcon (ALC) Q1 2026 Earnings Call Transcript - AOL.com
BTIG lowers Alcon stock price target to $82 on lower valuation - Investing.com UK
BTIG lowers Alcon stock price target to $82 on lower valuation By Investing.com - Investing.com Australia
Alcon stock slides as Q1 sales miss expectations and reported profitability drops sharply - Quiver Quantitative
Alcon Kicks Off 2026 on Solid Results as New Innovations Pay Dividends - Morningstar
Alcon Q1 2026 Earnings Call Transcript - Benzinga
Alcon Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
BofA Securities Maintains Alcon(ALC.US) With Sell Rating, Maintains Target Price $70.39 - Moomoo
BofA Securities Maintains Alcon(ALC.US) With Sell Rating, Cuts Target Price to $70.38 - Moomoo
Swiss eye care firm Alcon’s quarterly revenue rises less than expected - WHTC
Alcon slides after revenue misses forecasts, operating profit falls sharply By Investing.com - Investing.com Canada
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.78%
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):